Gain-of-Function Variant p.Pro2555Arg of von Willebrand Factor Increases Aggregate Size through Altering Stem Dynamics

Volker Huck, Po‐Chia Chen, Emma-Ruoqi Xu, Alexander Tischer, Ulrike Klemm, Camilo Aponte‐Santamaría, Christian Meß, Tobias Obser, Fabian Kutzki, Gesa König, Cécile V. Denis, Frauke Gräter, Matthias Wilmanns, Matthew Auton, Stefan W. Schneider, Reinhard Schneppenheim, Janosch Hennig, Maria A. BrehmThrombosis 2020 · DOI

Abstract

The multimeric plasma glycoprotein (GP) von Willebrand factor (VWF) is best known for recruiting platelets to sites of injury during primary hemostasis. Generally, mutations in the VWF gene lead to loss of hemostatic activity and thus the bleeding disorder von Willebrand disease. By employing cone and platelet aggregometry and microfluidic assays, we uncovered a platelet GPIIb/IIIa-dependent prothrombotic gain of function (GOF) for variant p.Pro2555Arg, located in the C4 domain, leading to an increase in platelet aggregate size. We performed complementary biophysical and structural investigations using circular dichroism spectra, small-angle X-ray scattering, nuclear magnetic resonance spectroscopy, molecular dynamics simulations on the single C4 domain, and dimeric wild-type and p.Pro2555Arg constructs. C4-p.Pro2555Arg retained the overall structural conformation with minor populations of alternative conformations exhibiting increased hinge flexibility and slow conformational exchange. The dimeric protein becomes disordered and more flexible. Our data suggest that the GOF does not affect the binding affinity of the C4 domain for GPIIb/IIIa. Instead, the increased VWF dimer flexibility enhances temporal accessibility of platelet-binding sites. Using an interdisciplinary approach, we revealed that p.Pro2555Arg is the first VWF variant, which increases platelet aggregate size and shows a shear-dependent function of the VWF stem region, which can become hyperactive through mutations. Prothrombotic GOF variants of VWF are a novel concept of a VWF-associated pathomechanism of thromboembolic events, which is of general interest to vascular health but not yet considered in diagnostics. Thus, awareness should be raised for the risk they pose. Furthermore, our data implicate the C4 domain as a novel antithrombotic drug target.

Introduction

Von Willebrand Factor (VWF) is a massive, multimeric protein essential for stopping bleeding; it acts like molecular "glue" that recruits platelets to injury sites. Traditionally, clinical research has focused on mutations that cause loss of function, leading to von Willebrand disease (VWD). However, there is growing interest in variants that make VWF hyperactive, potentially contributing to thromboembolic events like strokes or heart attacks. This study investigates the rare variant p.Pro2555Arg, located in the C4 domain, which exhibits a prothrombotic gain-of-function (GOF).

Structural Basis of Hyperactivity

To understand how a single mutation in the C4 domain influences VWF behavior, researchers analyzed the protein's structural dynamics. Surprisingly, the mutation does not make the C4 domain "stickier" by increasing its baseline binding affinity for platelet receptors. Instead, it alters the mechanical stability of the VWF "stem."

Structural overview of VWF monomer (A), the C4 domain mutation site (B), and the dimeric bouquet model (C).

VWF normally exists in a "zipped" or "bouquet" conformation that shields certain binding sites. The p.Pro2555Arg mutation destabilizes this arrangement, lowering the energy barrier for the stem to "unzip" under the mechanical forces of blood flow (shear stress). This increased flexibility makes platelet-binding sites more temporally accessible, effectively keeping the protein in an active state longer.

Functional Impact and Key Results

The prothrombotic effect of the p.Pro2555Arg variant was confirmed through both static and flow-based assays. While binding affinity remained unchanged, the functional outcome under shear was dramatic.

Cone and Platelet Aggregometry (CPA) results showing a significant increase in aggregate size (AS) for the p.Pro2555Arg variant compared to wild-type VWF (wtVWF).

Key findings include:

  • Increased Aggregate Size: In CPA assays, the variant significantly increased the mean aggregate size. In microfluidic assays at high shear (4,000 s⁻¹), the variant produced aggregates with a mean area of 5,041 µm², a sixfold increase compared to 853 µm² for wild-type VWF.
  • Molecular Extension: Small-Angle X-ray Scattering (SAXS) data confirmed that the mutant dimer is more extended, with a maximum dimension of 56 nm compared to the wild-type's 35 nm.
  • Structural Disorder: Circular dichroism revealed a 20% reduction in ordered secondary structure in the mutant, indicating local unfolding that contributes to its hyper-flexibility.

Conclusion

The p.Pro2555Arg variant represents a novel pathomechanism where a mutation in the VWF stem region leads to shear-dependent hyperactivity. These findings suggest that screening for such GOF variants could be a vital diagnostic tool for patients with unexplained thrombophilia. Furthermore, the C4 domain's role in regulating stem dynamics identifies it as a promising target for new antithrombotic therapies that could prevent clotting without the high bleeding risks associated with traditional anticoagulants.

Summary updated

Abstract

The multimeric plasma glycoprotein (GP) von Willebrand factor (VWF) is best known for recruiting platelets to sites of injury during primary hemostasis. Generally, mutations in the <i>VWF</i> gene lead to loss of hemostatic activity and thus the bleeding disorder von Willebrand disease. By employing cone and platelet aggregometry and microfluidic assays, we uncovered a platelet GPIIb/IIIa-dependent prothrombotic gain of function (GOF) for variant p.Pro2555Arg, located in the C4 domain, leading to an increase in platelet aggregate size. We performed complementary biophysical and structural investigations using circular dichroism spectra, small-angle X-ray scattering, nuclear magnetic resonance spectroscopy, molecular dynamics simulations on the single C4 domain, and dimeric wild-type and p.Pro2555Arg constructs. C4-p.Pro2555Arg retained the overall structural conformation with minor populations of alternative conformations exhibiting increased hinge flexibility and slow conformational exchange. The dimeric protein becomes disordered and more flexible. Our data suggest that the GOF does not affect the binding affinity of the C4 domain for GPIIb/IIIa. Instead, the increased VWF dimer flexibility enhances temporal accessibility of platelet-binding sites. Using an interdisciplinary approach, we revealed that p.Pro2555Arg is the first VWF variant, which increases platelet aggregate size and shows a shear-dependent function of the VWF stem region, which can become hyperactive through mutations. Prothrombotic GOF variants of VWF are a novel concept of a VWF-associated pathomechanism of thromboembolic events, which is of general interest to vascular health but not yet considered in diagnostics. Thus, awareness should be raised for the risk they pose. Furthermore, our data implicate the C4 domain as a novel antithrombotic drug target.
BibTeX
@inproceedings{huck2020gain,
  author = {Volker Huck and Po‐Chia Chen and Emma-Ruoqi Xu and Alexander Tischer and Ulrike Klemm and Camilo Aponte‐Santamaría and Christian Meß and Tobias Obser and Fabian Kutzki and Gesa König and Cécile V. Denis and Frauke Gräter and Matthias Wilmanns and Matthew Auton and Stefan W. Schneider and Reinhard Schneppenheim and Janosch Hennig and Maria A. Brehm},
  title = {{Gain-of-Function Variant p.Pro2555Arg of von Willebrand Factor Increases Aggregate Size through Altering Stem Dynamics}},
  booktitle = {Thrombosis},
  year = {2020},
  doi = {10.1055/a-1344-4405},
}
Figure